Avella Specialty Pharmacy Recalls Sterile Products

News
Article

Avella issued a nationwide recall of sterile products produced at the Advanced Pharma Houston location due to inaccurate labeling.

On Feb. 23, 2017, Advanced Pharma, Inc. d/b/a Avella of Houston announced it was voluntarily recalling all unexpired sterile injectable products because products labeled “latex free” may contain synthetic latex and/or natural latex. The recalled products were produced at the company’s Houston, TX location from Sept. 1, 2016–Feb. 16, 2017 and were distributed to healthcare facilities.

While it has not yet received any reports of adverse events, the company is recalling the products out of caution because it cannot be confirmed whether the “latex free” statement is accurate in all cases. According to the company, allergic reactions to latex may include swelling and inflammation and could be life threatening.

The company recommends healthcare facilities discontinue use of the products and return unused portions to Avella Specialty Pharmacy. Adverse events may be reported to FDA at the agency’s website

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes